Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
Status:
Completed
Trial end date:
2021-08-24
Target enrollment:
Participant gender:
Summary
The objective of this Surveillance is to verify the following subject matters concerning
Tofacitinib (Xeljanz) under general practice.
1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy
2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy
Occurrences of malignant tumors and serious infections will be compared with a control group.